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ABSTRACT We have studied the effects of C28R2, a basic peptide derived from the autoinhibitory domain of the plasma
membrane Ca-ATPase, on enzyme activity, oligomeric state, and E1-E2 conformational equilibrium of the Ca-ATPase from
skeletal and cardiac sarcoplasmic reticulum (SR). Time-resolved phosphorescence anisotropy (TPA) was used to determine
changes in the distribution of Ca-ATPase among its different oligomeric species in SR. C28R2, at a concentration of 1–10 M,
inhibits the Ca-ATPase activity of both skeletal and cardiac SR (CSR). In skeletal SR, this inhibition by C28R2 is much greater
at low (0.15 M) than at high (10 M) Ca2, whereas in CSR the inhibition is the same at low and high Ca2. The effects of
the peptide on the rotational mobility of the Ca-ATPase correlated well with function, indicating that C28R2-induced protein
aggregation and Ca-ATPase inhibition are much more Ca-dependent in skeletal than in CSR. In CSR at low Ca2,
phospholamban (PLB) antibody (functionally equivalent to PLB phosphorylation) increased the inhibitory effect of C28R2
slightly. Fluorescence of fluorescein 5-isothiocyanate-labeled SR suggests that C28R2 stabilizes the E1 conformation of the
Ca-ATPase in skeletal SR, whereas in CSR it stabilizes E2. After the addition of PLB antibody, C28R2 still stabilizes the E2
conformational state of CSR. Therefore, we conclude that C28R2 affects Ca-ATPase activity, conformation, and self-
association differently in cardiac and skeletal SR and that PLB is probably not responsible for the differences.
INTRODUCTION
The SERCA-type Ca-ATPases pump Ca2 from sarcoplasm
into the sarcoplasmic reticulum (SR) lumen to allow relax-
ation of muscle. The plasma membrane Ca-ATPase
(PMCA)-type Ca-ATPase pumps Ca2 into the cell across
the plasma membrane. Although the sequence homology is
only 30% between SERCA1-type pumps (usually obtained
from rabbit fast-twitch muscle) and PMCA-type pumps
(usually obtained from human erythrocytes), secondary
structure predictions suggest similarities in the overall ar-
rangement of important structural and functional domains
(Verma et al., 1988; Strehler, 1991). Cardiac SR (CSR)
Ca-ATPase (SERCA2a, usually obtained from dog hearts)
is regulated by phospholamban (PLB) (Lindemann et al.,
1983), which inhibits the cardiac Ca-ATPase by decreasing
its apparent affinity for Ca2. This inhibition, which is
observed only at submicromolar Ca2, is released upon
phosphorylation of PLB either by cAMP-dependent protein
kinase (PKA) or by Ca-calmodulin-dependent protein ki-
nase II (CaM kinase II). The PMCA-type Ca-ATPases are
regulated directly by the binding of calmodulin to a highly
basic C-terminal region (autoinhibitory domain) of PMCA,
stimulating the pump by increasing both Ca2 affinity (a
decrease in KM) and maximum velocity (Vmax) (Enyedi and
Penniston, 1993). Photoactivable derivatives of PLB and the
calmodulin-binding domain of PMCA, respectively, have
been shown to cross-link to their respective pumps at struc-
turally homologous regions (Enyedi and Penniston, 1993).
Although the regulatory mechanisms of SERCA and PMCA
by phospholamban and calmodulin, respectively, are well
established at the functional level, the physical mechanism
of interaction of these regulatory molecules with the pumps
and the resulting physical changes in the pumps are not
understood at the molecular level.
Previous investigations into the regulatory mechanisms
of the SR Ca-ATPase in skeletal muscle have established
the importance of the oligomeric state of the Ca-ATPase to
its enzymatic function (Squier et al., 1988a; Voss et al.,
1991; Karon and Thomas, 1993). Agents that aggregate the
Ca-ATPase in skeletal SR, such as chemical cross-linkers,
the amphipathic peptide melittin, or the local anesthetic
lidocaine, inhibit enzymatic activity (Squier et al., 1988a;
Mahaney and Thomas, 1991; Voss et al., 1991; Kutchai et
al., 1994). Agents that dissociate aggregates of the Ca-
ATPase, such as the volatile anesthetics ether and halo-
thane, activate the enzyme (Bigelow and Thomas, 1987;
Birmachu et al., 1989; Karon and Thomas, 1993).
In CSR, PLB inhibits the enzymatic activity of the Ca-
ATPase (James et al., 1989a; Sham et al., 1991) at low Ca2
(submicromolar) concentrations, and this inhibition corre-
lates with a decreased rotational mobility of the Ca-ATPase,
compared to the rotational mobility at high Ca2 or after
PLB phosphorylation (Voss et al., 1994). Upon PLB phos-
phorylation or addition of micromolar Ca2 (high Ca2),
the resting inhibition of the Ca-ATPase is relieved (the
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enzyme is activated), and this activation correlates with an
increase in the rotational mobility of the Ca-ATPase. Thus
the regulation of CSR Ca-ATPase by phosphorylation and
dephosphorylation of PLB may involve the self-association
and dissociation of the Ca-ATPase.
C28R2, an amphipathic peptide, corresponds to 28 resi-
dues of the highly basic C-terminal calmodulin-binding
domain of the erythrocyte plasma membrane Ca-ATPase
(rPMCA2b). This region of the PMCA forms part of the
enzyme’s autoinhibitory domain, which shares functional
features with PLB (Vorherr et al., 1992). It has been re-
ported that this positively charged peptide inhibits both
PMCA and the skeletal SR Ca-ATPase (Enyedi and Pen-
niston, 1993). The aim of the present study is to characterize
the effects of C28R2 on the enzymatic activity and oligo-
meric state of the Ca-ATPase in both cardiac and skeletal
SR. Because the rotational dynamics and oligomeric state of
the Ca-ATPase play key roles in modulating Ca-ATPase
activity, it is important to understand the underlying mech-
anisms relating these physical properties to the enzyme’s
kinetic behavior. The results shed light on similarities and
differences in the physical principles that govern the enzy-
matic mechanisms and regulation of these three different
Ca-ATPase systems.
MATERIALS AND METHODS
Reagents
Erythrosin-5-isothiocyanate (ErITC) and fluorescein-5-isothiocyanate
(FITC) were obtained from Molecular Probes (Eugene, OR) and stored in
N,N-dimethylformamide (DMF) under liquid nitrogen. Catalase, glucose
oxidase, -D-glucose, pyruvate kinase, lactate dehydrogenase, phospho-
enol pyruvate, ATP, and NADH (-nicotinamide adenine dinucleotide,
reduced form) were purchased from Sigma (St. Louis, MO). The calcium
ionophore A23187 was obtained from Calbiochem (San Diego, CA).
C28R2 peptide was synthesized chemically (Enyedi et al., 1991) and
dissolved in water containing 1 mM dithiothreitol (DTT). The monoclonal
anti-PLB antibody 2D12 (PLB Ab) (Cantilina et al., 1993) was kindly
provided by Dr. Larry Jones (University of Indiana).
Preparation of SR
All SR preparations were made at 4°C. SR vesicles were prepared from the
fast twitch skeletal muscle of New Zealand white rabbits (Fernandez et al.,
1980), then purified on a discontinuous sucrose gradient (Birmachu et al.,
1989) to separate Ca-ATPase-rich light SR (LSR) from heavy and inter-
mediate SR vesicles (junctional SR-containing calcium release proteins).
LSR was resuspended in 0.3 M sucrose, 20 mM 3-(N-morpholino)propane-
sulfonic acid (MOPS) (pH 7.0); rapidly frozen in 4-mg aliquots; and stored
in liquid nitrogen until use. Based on sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis, LSR contained 7 nmol Ca-ATPase/mg SR
protein, corresponding to 80% of the total protein by weight. The LSR
vesicles thus prepared are tightly sealed, as indicated by Ca2 ionophore
(A23187) stimulation of ATPase activity. Cardiac sarcoplasmic reticulum
(CSR) prepared from canine ventricular tissue was kindly provided by Dr.
Joseph J. Feher (Feher and Briggs, 1983).
ATPase assay
Ca-ATPase activity was measured at 25°C using an enzyme-linked, con-
tinuous spectrophotometric assay (Karon et al., 1994). The standard assay
mix contained between 5 and 50 g of SR vesicles in 0.5 ml of buffer
containing 50 mM MOPS (pH 7.0), 60 mM KCl, 2 mM MgCl2, 5 mM
EGTA, 0.42 mM phosphoenolpyruvate, 0.15 mM NADH, 3.75 I.U. of
pyruvate kinase, and 9.0 I.U. of lactate dehydrogenase. The assay mixture
also contained 1 g/ml of the ionophore A23187 (added from DMF; the
final DMF concentration was less than 1%, v/v) to prevent a buildup of
calcium inside the vesicles that might inhibit the Ca-ATPase activity. An
aliquot of CaCl2 solution was added to the assay mix to give either 10 M
(high Ca2) or 0.15 M (low Ca2) free Ca2. C28R2 dissolved at 1.0
mg/ml in water containing 1 mM DTT was added to the samples and
allowed to incubate for 5 min before data collection. Mg-ATP (to a final
concentration of 1 mM) was added to start the assay, and the absorbance
of NADH was followed at 340 nm to determine the amount of ATP
hydrolyzed. Experiments in the presence of PLB Ab were performed by
incubating Ab (1:2 Ab:Ca-ATPase by weight) at 25°C for 20 min before
the start of the ATPase assay.
Labeling of LSR with ErITC and FITC
For phosphorescence experiments, the Ca-ATPase in SR vesicles was
specifically labeled with ErITC as described previously (Birmachu and
Thomas, 1990), and the final labeled LSR was suspended in 25 mMMOPS
(pH 7.0), 0.3 M sucrose, and 0.1 mM CaCl2. For fluorescence experiments,
the Ca-ATPase in SR was specifically labeled with FITC as described
previously (Voss et al., 1995).
Fluorescence of FITC-labeled SR
The fluorescence intensity of 1 M FITC-SR was measured with a SPEX
Fluorolog II fluorimeter (ex  495 nm, em  520 nm) by summing the
total fluorescence emission over 20 s. This was repeated four times per
sample. The experiments were performed in the standard buffer containing
50 mM MOPS, 60 mM KCl, 2 mM MgCl2, and 1 mM EGTA, or 0.1 mM
CaCl2 (pH 7.0). Fluorescence changes were calculated as described previ-
ously, after the addition of CaCl2 or EGTA (Karon et al., 1994).
Time-resolved phosphorescence anisotropy
Phosphorescence anisotropy was measured in a buffer containing 50 mM
MOPS (pH 7.0), 60 mM KCl, 2 mM MgCl2, 5 mM EGTA, with CaCl2
added to give the required free [Ca2]. Oxygen was enzymatically re-
moved from the sample by the addition of 200 g/ml glucose oxidase, 30
g/ml catalase, and 5 mg/ml -D-glucose (Eads et al., 1984). Deoxygen-
ation was carried out in a sealed cuvette containing 0.2–0.3 mg of SR
protein/ml for 15–25 min before phosphorescence data collection. C28R2
stock solution was added to the SR in a manner analogous to that used for
ATPase activity measurements. Phosphorescence anisotropy decays were
obtained as described previously (Ludescher and Thomas, 1988). The
time-dependent anisotropy r(t) is given by
rt Ivv GIvh/Ivv 2GIvh (1)
where Ivv and Ivh are obtained by signal-averaging the time-dependent
phosphorescence decays following 2000 laser pulses, with a single detector
and a polarizer that alternates between the vertical (Ivv) and horizontal (Ivh)
positions every 2000 pulses. The laser repetition rate was 200 Hz, so a
typical r(t) acquisition required 4 min to complete 10 loops, or cycles of
4000 laser pulses each (2000 in each orientation). G is an instrumental
correction factor, determined by measuring the anisotropy of free dye in
solution under experimental conditions.
TPA data analysis
Phosphorescence anisotropy decays were analyzed as described previously
(Birmachu and Thomas, 1990), using a nonlinear least-squares fit to a sum
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of exponentials plus a constant:
rt/r0 
i1
3
Aie
t/	i A
 (2)
where i are rotational correlation times, Ai are normalized amplitudes
(ri/ro), A
 is the normalized final anisotropy (r
/ro), and ro is the initial
anisotropy (r(0)  r0  ri  r
). The goodness of fit for the anisotropy
decays was evaluated by comparing 	2 values for the multiexponential fits
and by comparing plots of the residuals (the difference between the
measured and the calculated decays). Phosphorescence lifetimes were
determined by fitting the total intensity (Ivv  2Ivh) to a sum of exponen-
tials in a manner analogous to that of the anisotropy decay fitting (Birma-
chu and Thomas, 1990). C28R2, at the concentrations used in the experi-
ments, did not have significant effects on phosphorescence lifetimes.
In the present study we have also fit data to an analytical uniaxial
rotation model (Belford et al., 1972) that explicitly incorporates all of the
factors that determine the anisotropy decay kinetics of uniaxially rotating
chromophores:
rt 
i1
n
xirit xIr0 (3)
where xi is the mole fraction associated with the ith rotating species, and xI
is the mole fraction of Ca-ATPase that does not rotate on the time scale of
the experiment (immobile Ca-ATPase). Using this expression, changes in
the mole fraction of immobile Ca-ATPase induced by SR perturbants can
be directly determined, independently of the orientation of the probe
(Mersol et al., 1995).
The expression for the individual anisotropy of the ith uniaxially rotat-
ing species (Szabo, 1984) is
rit 
a1e
Dit a2e
4Dit a3 (4)
where
a1 1.2sin a cos a sin e cos e cos 	ae (5a)
a2 0.3sin2a sin2e cos 2	ae (5b)
a3 0.23 cos2a 13 cos2e 1 (5c)
Here Di is the rotational diffusion coefficient about an axis normal to the
plane of the membrane, a and e are the angles between the probe’s
absorption and emission dipoles and the membrane normal, ae is the
azimuthal angle between the absorption and emission transition dipoles of
the probe, and 
 is the order parameter for fast (submicrosecond) rotation
of the probe with respect to the protein. The submicrosecond motion may
result from the site of probe attachment undergoing segmental motion or
from partial freedom of motion of the probe itself around its site of
attachment.
The uniaxial rotation model (Eqs. 3–5) explicitly accounts for 1) the
biexponential decay for each species (Eq. 4), 2) the order parameter 
 for
submicrosecond motion, and 3) the angular dependence of the amplitudes
of the exponentially decaying terms (Eqs. 5a–5c). We have observed
previously that transient phosphorescence anisotropy decays of ErITC-
labeled skeletal and CSR are best fit by including three uniaxially rotating
species (Karon et al., 1995; Mersol et al., 1995). Each species is assumed
to have the same values of a, e, and ae, and to differ from the other
species only in its diffusion coefficient, presumably because of differences
in aggregation state. Thus the n-component uniaxial model (Eqs. 4 and 5)
has three more variables to be fit than the n-component exponential model
(Eq. 3), but the addition of each component adds just two new parameters
for each model.
RESULTS
Effects of C28R2 on Ca-ATPase activity in LSR
and CSR
Enyedi and Penniston (1993) reported that C28R2 inhibited
Ca-ATPase activity in skeletal SR. We have measured the
effects of C28R2 on Ca-ATPase activity in skeletal and
CSR at low (150 nM) and high (10 M) Ca2. Our results
show that this peptide at micromolar concentration strongly
inhibits Ca-ATPase activity not only in skeletal SR, but also
in CSR, and that the inhibition occurs at both high and low
Ca2 concentrations (Fig. 1). In skeletal SR, inhibition was
substantially greater at low Ca2 than at high Ca2 (Fig. 1
A), whereas in CSR, the inhibition was essentially indepen-
dent of [Ca2] (Fig. 1 B). At low Ca2, the inhibition by
C28R2 is greater in skeletal SR than in CSR; at high Ca2,
inhibition was greater in CSR than in skeletal SR. In skeletal
SR, C28R2 was shown to be very effective in increasing the
K0.5 for Ca
2 and decreasing the maximum velocity of the
enzyme (Enyedi and Penniston, 1993). In CSR, our studies
indicate that C28R2 effects only the maximum velocity of
the enzyme (Fig. 2).
To determine whether the differences between skeletal
and CSR are due to the presence of phospholamban (PLB)
in CSR, we tested the effects of C28R2 on CSR in the
presence of PLB Ab, which is functionally equivalent to
PLB phosphorylation, relieving the inhibition that is caused
by PLB at low Ca2 (Cantilina et al., 1993). PLB Ab had no
significant effect on the C28R2-induced inhibition of Ca-
ATPase in CSR at low Ca2 (Fig. 3). We also measured the
effects of C28R2 on Ca-ATPase activity in CSR after re-
moving PLB with Triton (Nakamura et al., 1983) and did
not observe a significant change in [Ca2] dependence (data
not shown). It is clear that the different [Ca2] dependence
of inhibition by C28R2 is due to isoform differences, not to
PLB.
FIGURE 1 Effect of C28R2 on Ca-ATPase activity (normalized to the
activity in the absence of C28R2 at each Ca2 concentration), in skeletal
SR (A) and CSR (B), at 10 M Ca2 (f) and 0.15 M Ca2 (F), at 25°C.
Mean  SEM (n  3).
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Effects of C28R2 on the rotational dynamics of
the Ca-ATPase
We used time-resolved phosphorescence anisotropy (TPA)
to determine the effects of C28R2 on the rotational dynam-
ics of the Ca-ATPase in skeletal and CSR at high and low
Ca2. When C28R2 was added to ErITC-labeled skeletal
SR, it decreased the amplitude of decay of anisotropy in a
concentration-dependent manner (Fig. 4), resulting in an
increase in the final anisotropy (A
). Anisotropy decay rates
did not change significantly compared to the amplititudes of
the decay, in response to the concentration of C28R2. Sim-
ilar effects were observed in CSR at low and high Ca2
(Fig. 5). The decays were best fit to a sum of three expo-
nentials plus a constant residual anisotropy (Eq. 2, n  3),
as described previously (Birmachu and Thomas, 1990;
Karon and Thomas, 1993; Mersol et al., 1995). The three
components represent approximately the rotational mobility
of Ca-ATPase monomers (A1), small oligomers (A2), and
larger oligomers (A3). The final anisotropy (A
) increases
with the mole fraction of species that are too large to rotate
appreciably on the time scale of the experiment (Eq. 3)
(Birmachu and Thomas, 1990). C28R2 increased the rota-
tional correlation times (decreased rotational rates) of all
three rotating components slightly in LSR, but had little
effect on the rotational correlation times in CSR. As indi-
cated in the Discussion, similar conclusions were reached
when the more explicit uniaxial diffusion model (Eqs. 4 and
5) was considered.
In skeletal SR, treatment with C28R2 increased the value
of A
 (Fig. 6 A), with a decrease in the amplitudes associ-
ated with smaller ATPase oligomers (A1 and A2). Values of
A3 (larger, but not immobile, oligomers) were increased at
high Ca2, but changed only slightly at low Ca2. In CSR,
C28R2 also resulted in an increase in the proportion of the
immobile species, A
 (Fig. 6 B), with decreases in the
values of A1, A2, and A3, suggesting that C28R2 induces the
formation of large, immobile oligomers from monomers
and larger mobile oligomers. In skeletal SR, increased A

induced by C28R2 is more extensive at low Ca2 than at
high Ca2 (Fig. 6 A). However, in CSR, we did not observe
any significant difference in the increase in A
 caused by
C28R2 at high and low Ca2 (Fig. 6 B).
FIGURE 3 Effect of C28R2 on Ca-ATPase activity (normalized to the
activity in the absence of C28R2 at each Ca2 concentration) in CSR at
0.15 M Ca2 (low Ca) in the absence (f) and presence (F) of PLB Ab,
at 25°C. Mean  SEM (n  3).
FIGURE 5 Time-resolved phosphorescence anisotropy (TPA) decays of
ErITC-labeled CSR at 0.15 M Ca2 (A) and 10 M Ca2 (B), in the
presence of the indicated concentrations of C28R2.
FIGURE 2 Ca2 dependence of Ca-ATPase activity in CSR in the
absence (f) and presence (F) of 15 M C28R2, at 25°C. Mean  SEM
(n  3).
FIGURE 4 Time-resolved phosphorescence anisotropy (TPA) decays of
ErITC-labeled skeletal SR at 0.15 M Ca2 (A) and 10 M Ca2 (B), in
the presence of the indicated concentrations of C28R2, at 25°C.
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Effects of C28R2 on the fluorescence of
FITC-labeled skeletal and CSR
The fluorescence intensity of covalently bound FITC, a
fluorescent probe similar in structure to ErITC, is sensitive
to the E1/E2 conformational changes in the Ca-ATPase.
Although it is not possible to determine quantitatively the
E1/E2 equilibrium constant from FITC fluorescence, we
can determine the direction in which this equilibrium is
perturbed (Froud and Lee, 1986; Sagara et al., 1992). These
changes probably reflect changes in rate constants, which in
turn determine enzyme turnover rates. The addition of Ca2
after EGTA decreases FITC fluorescence, indicating a dec-
crease in E2/E1 (Fig. 7, left panels), whereas the addition of
EGTA after Ca2 increases fluorescence, indicating a de-
crease in E2/E1 (Fig. 7, right panels).
In FITC-labeled skeletal SR, C28R2 decreased fluores-
cence, indicating a decrease in E2/E1, at both low Ca2
(Fig. 7, top left panel) and high Ca2 (Fig. 7, top right
panel). In contrast, in FITC-labeled CSR, C28R2 increased
fluorescence, indicating an increase in E2/E1, at both low
Ca2 (Fig. 7, lower left panel) and high Ca2 (Fig. 7, lower
right panel). This different response to the peptide in skel-
etal and CSR was not affected by PLB Ab (Fig. 7, lower
left), indicating that PLB is not responsible for the difference.
DISCUSSION
Effects of C28R2 on Ca-ATPase activity
It has been found previously that the positively charged
amphipathic peptide melittin inhibits the Ca-ATPase of
skeletal SR while inducing large-scale aggregation of the
enzyme through electrostatic interactions (Voss et al.,
1995). Systematically decreasing the positive charge of
melittin by acetylation decreased the inhibition and oli-
gomerization of the Ca-ATPase (Voss et al., 1995). Simi-
larly, the positively charged local anesthetic lidocaine in-
hibits and aggregates the Ca-ATPase in both skeletal and
CSR, suggesting that lidocaine-induced inhibition may be
due to cationic interaction with the hydrophilic (anionic)
cytoplasmic domain of the Ca-ATPase (Karon et al., 1995).
Similarly, it has been suggested that phospholamban (PLB)
interacts with the cardiac Ca-ATPase, through its positively
charged cytoplasmic domain, and inhibits pump activity
while inducing large-scale aggregation of the pump (Voss et
al., 1994, 1995). Ca-pump aggregation, like inhibition, is
induced by PLB only at low Ca2 and can be relieved by
either PLB phosphorylation or micromolar Ca2 (Voss et
al., 1994). The positively charged synthetic peptide C28R2
has been shown to inhibit PMCA-type Ca-ATPase (Enyedi
et al., 1991) and the SERCA1 Ca-ATPase in skeletal SR
(Enyedi and Penniston, 1993). The inhibition by this peptide
is due to its direct interaction with the pump, rather than to
an effect on membrane permeability or on a Ca2 channel
(Enyedi and Penniston, 1993).
In the present study, we found that C28R2 at micromolar
levels strongly inhibits Ca-ATPase activity both in skeletal
and CSR (Fig. 1). In skeletal SR, we found that this inhi-
bition is greatest at submicromolar Ca2 (Fig. 1 A), con-
firming previous reports that this peptide decreases not only
the maximum velocity of SERCA1 at micromolar Ca2
(Vmax), but also the apparent Ca
2 affinity (K0.5) (Enyedi
and Penniston, 1993). In contrast, we report that the C28R2
inhibition in CSR (SERCA2a) is Ca-independent (Fig. 1 B),
and the effect is only on maximum velocity (Vmax) (Fig. 2).
This could be due either to a structural difference between
the two isoforms, or to the presence of phospholamban
(PLB) in CSR. However, the addition of PLB Ab to CSR,
which eliminates the influence of PLB on the Ca-ATPase
FIGURE 6 Effects of C28R2 on the final anisotropy (A
) of ErITC-
labeled skeletal SR (A) and CSR (B) at 10 M Ca2 (f) and 0.15 M
Ca2 (F). A
 was determined by fitting the TPA decay to Eq. 2, then
normalized to the control (no C28R2). Mean  SEM (n  3).
FIGURE 7 Fluorescence intensity changes of FITC-labeled SR in re-
sponse to C28R2. Fluorescence intensity changes were measured in stan-
dard buffer containing either 1 mM EGTA (control, represents E2 state) or
100 M Ca2 (control, represents E1 state) at 25°C. C28R2 (5 M) was
added to FITC-labeled SR in standard buffer containing either 1 mM
EGTA or 100 M Ca2 in the absence or presence of PLB Ab (for CSR
in EGTA), followed by the addition of either 1 mM Ca2 (to EGTA buffer
to change [Ca2] from 0 to 20 M) or 0.5 mM EGTA (to Ca2 buffer to
change [Ca2] from 100 M to 100 nM). The fluorescence intensities were
measured before and after the addition of either EGTA or Ca2 and
expressed as a percentage change. Fluorescence changes were calculated as
described previously (Karon et al., 1994). Data represent the mean  SEM
(n  3).
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(Cantilina et al., 1993), did not significantly change the
extent of inhibition of the Ca-ATPase by C28R2 at low
Ca2 (0.15 M) (Fig. 3), where the effects of PLB are
greatest (Tada and Katz, 1982). We conclude that the two
Ca-ATPase isoforms differ in their susceptibility to C28R2,
suggesting either a difference in the binding site for this
peptide, or a difference in the effect of Ca2 on this site.
These results also suggest that the binding site on the
Ca-ATPase and the mechanism of inhibition are different
for C28R2 and PLB.
The apparent KI for inhibition of the Ca-ATPase by
C28R2 is in the range of 2–5 M. Because this is signifi-
cantly higher than the concentration of the Ca-ATPase in
enzymatic and spectroscopic measurements, and because
peptide binding was not measured directly, we cannot rule
out the possibility that the binding stoichiometry is greater
than 1, i.e., that there might not be a single site on the pump
for binding and inhibition. Similarly, the stoichiometry and
specificity whereby phospholamban inhibits the SERCA2a
pump are not known.
Effects of C28R2 on the oligomeric state of the
Ca-ATPase
Previous studies of both skeletal and CSR demonstrated that
several perturbants that inhibit the Ca-ATPase activity also
promote the formation of larger oligomers of the pump
(Bigelow et al., 1986; Bigelow and Thomas, 1987; Squier
and Thomas, 1988; Squier et al., 1988a; Birmachu and
Thomas, 1990; Karon and Thomas, 1993; Voss et al., 1991,
1994). In contrast, perturbants that promote the dissociation
of larger oligomers of the Ca-ATPase into smaller oli-
gomers consistently increased its activity (Voss et al., 1991,
1994; Kutchai et al., 1994; Mahaney et al., 1992). In the
present study, TPA was used to investigate the effects of
C28R2 on the oligomeric state of the Ca-ATPase in the SR
membrane. The addition of C28R2 at low and high Ca2
results in a decreased amplitude of anisotropy decay in both
skeletal (Fig. 4) and cardiac (Fig. 5) SR, with a resulting
increase in A
 (Fig. 6). In skeletal SR, the large increase in
A
 at low Ca
2 and the moderate increase in A
 at high
Ca2 with increasing [C28R2] closely correlate with the
inhibition of ATPase activity (Fig. 1 A). Moreover, the
parallel increase in A
 values at low and high Ca
2 with
increasing concentrations of C28R2 correlate well with the
parallel decreases in ATPase activity in CSR (Fig. 1 B).
A change in the final anisotropy A
 may be due to 1) a
change in the fraction of immobile Ca-ATPase oligomers or
2) a change in the angle between the membrane normal and
the probe’s absorption and emission dipoles (Mersol et al.,
1995). It has been shown that other perturbants (such as
halothane, thapsigargin, lidocaine, and C12E8) affect the
rapid submicrosecond motion of the ErITC probe bound to
skeletal and cardiac Ca-ATPase by changing the mole frac-
tion of immobile Ca-ATPase oligomers, but do not affect
the probe angles (Karon et al., 1995; Mersol et al., 1995; Shi
et al., 1996). We fit TPA data to the model of uniaxial
rotation (Eqs. 3–5), which explicitly considers both the
mole fraction of pumps in immobile oligomers (xI) and the
probe angles. We found that the immobile fraction xI in-
creased in both skeletal SR and CSR, both at low Ca2
(Fig. 8, A and C) and at high Ca2 (not shown), but that the
the probe angles did not change (Fig. 8, B and D). There-
fore, C28R2-induced increases in A
 probably represent
Ca-ATPase aggregation, which correlates with enzymatic
inhibition.
The erythrocyte plasma membrane Ca-ATPase (PMCA
type) is regulated by calmodulin. The enzyme is more active
in the dimeric form than in the monomeric form (Kosk-
Kosicka et al., 1989). In our studies, C28R2-induced oli-
gomerization (oligomers much larger than dimers) of Ca-
ATPase correlates with the inhibition of enzymatic activity.
The response of enzymatic activity of skeletal SR to halo-
thane (Karon and Thomas, 1993) at 25°C and the response
of CSR to quercetin (Mckenna et al., 1996) were shown to
be biphasic. At low concentrations, halothane in skeletal SR
(Karon and Thomas, 1993) and quercetin in CSR (Mckenna
et al., 1996) activate the Ca-ATPase activity. As the con-
centration of the drugs increased, Ca-ATPase activity was
inhibited. Our previous data suggest that the formation of
smaller oligomers in response to low concentration of per-
turbants correlates with enzyme activation (or no effect),
and the formation of larger oligomers in response to higher
concentrations correlates with inhibition of the Ca-ATPase
in SR. We propose that the inhibition of both skeletal and
CSR Ca-ATPase activity in response to C28R2 is due to the
formation of much larger oligomers. However, the mecha-
nism of regulation of SERCA1 or SERCA2a by C28R2
cannot be correlated directly with that of PMCA regulation,
FIGURE 8 Analysis of TPA data based on the model of uniaxial rotation
(Eq. 3). The mole fractions (A, C) of mobile Ca-ATPase species x1, x2, and
x3 and immobile species xI and the angles describing the orientation of
probes relative to the membrane normal (B, D) were determined by fitting
TPA decays to Eq. 3 (n  3). Results are shown for skeletal SR (A, B) and
for CSR (C, D) at low (0.15 M) Ca2.
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because the specificity and the site of interaction of this
peptide with SERCA isoforms are not understood.
Effects of C28R2 on the conformational state of
Ca-ATPase
It has previously been shown in this laboratory that inhib-
itors that aggregate the Ca-ATPase also shift its conforma-
tional equilibrium toward the E2 forms: E2, E2P, and or
E2P(2Ca) (Karon et al., 1994). It has also been reported that
melittin shifted the enzyme’s E1-E2 conformational equi-
librium toward E2 at low Ca2 concentration in skeletal SR
(Voss et al., 1995). The detergent C12E8 increased the rate
of the E2-to-E1 transition and stabilized E2P (Andersen et
al., 1983; Champeil et al., 1986; Gould et al., 1986; de
Foresta et al., 1989) in skeletal SR. In the present study, in
skeletal SR we found that C28R2 shifted the equilibrium
toward E2 in the absence of Ca2 (Fig. 7, top left panel)
and, like C12E8, stabilized the E1 state in the presence of
Ca2 (Fig. 7, top right panel). Whereas, in CSR, C28R2,
like lidocaine, stabilized the E2 conformational state in the
absence of Ca2 (Fig. 7, lower left panel) and shifted the
equilibrium toward the E1 state in the presence of Ca2
(Fig. 7, lower right panel). In the presence of PLB Ab, there
is a greater increase in fluorescence intensity of FITC-
labeled CSR (representing a further stabilization of E2) in
response to C28R2 (Fig. 7, lower left panel), suggesting that
PLB is not responsible for the different effects of C28R2 in
CSR compared to skeletal SR. The differences in the effects
of C28R2 on SERCA1 at low and high Ca2 may be due to
the binding of the peptide to some low-affinity Ca2 bind-
ing site, which at high Ca2 is saturated by Ca2 and is no
longer available for the binding of C28R2. Alternatively,
C28R2 may bind at a site with a specific conformational
state in the presence of low Ca2, and a conformational
change at that site in the presence of high Ca2 may prevent
the binding of the peptide. The observed differences in
conformational equilibrium between skeletal and CSR at
low and high Ca2 in response to C28R2 may partly ac-
count for the differences in the inhibitory responses to
C28R2.
CONCLUSIONS
The effects of C28R2 on the rotational dynamics of the
Ca-ATPase show a strong correlation between activity and
oligomeric state in skeletal and CSR, indicating that this
peptide affects Ca-ATPase activity by causing self-associ-
ation of the enzyme. C28R2 inhibits and aggregates the
Ca-ATPase of both skeletal and CSR. Inhibition and aggre-
gation are Ca-dependent in skeletal SR, but not in CSR. The
effects of C28R2 on CSR Ca-ATPase are not significantly
altered by PLB Ab. C28R2 stabilizes the E1 conformational
state of the Ca-ATPase in skeletal SR, whereas in CSR it
stabilizes E2. After the addition of PLB Ab, C28R2 still
stabilizes the E2 conformational state in CSR. This suggests
that PLB is probably not responsible for the differences
observed between skeletal and CSR in response to C28R2.
Despite the significant sequence homology between
SERCA1-type (skeletal) and SERCA2-type (cardiac) Ca
pumps, there are differences in their response to various
inhibitory agents, such as general anesthetics and C28R2.
On the other hand, it is remarkable that an autoinhibitory
peptide from the PMCA enzyme, which has substantial
differences in sequence from the SERCA enzymes, has such
potent functional and physical effects on the SERCA
pumps. Future studies on the structural bases of these in-
hibitory effects should shed light on the relationship be-
tween structure and function in these Ca-ATPase isoforms.
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